Protective Effects of Diuretics Against the Development of Cardiovascular Disease in Patients with Chronic Kidney Disease: A Systematic Review

Author(s): Akinori Aomatsu, Susumu Ookawara, Kenichi Ishibashi, Yoshiyuki Morishita*

Journal Name: Cardiovascular & Hematological Agents in Medicinal Chemistry
Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents

Volume 16 , Issue 1 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Cardiovascular disease is one of the most important risk factors for mortality and morbidity in patients with Chronic Kidney Disease (CKD). This systematic review focuses on the protective effects of diuretics against the development of cardiovascular disease in patients with CKD. Among various kinds of diuretics, spironolactone, a mineralocorticoid receptor antagonist, has been shown to have protective effects against cardiovascular disease in patients with all stages of CKD, including predialysis, hemodialysis, and peritoneal dialysis. Low-dose loop diuretics have also been shown to have cardioprotective effects in patients with CKD during the pre-dialysis and hemodialysis stages; however, high-dose loop diuretics have failed to show these cardioprotective effects. The protective effects of other classes of diuretics, including thiazide and tolvaptan, against cardiovascular diseases in patients with CKD remain unclear.

Keywords: Diuretics, cardiovascular disease, chronic kidney disease, spironolactone, mineralocorticoid receptor antagonist, dialysis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 02 April, 2018
Page: [12 - 19]
Pages: 8
DOI: 10.2174/1871525716666180402145228
Price: $65

Article Metrics

PDF: 68
PRC: 1